deaths (OS)progression or deaths (PFS)RFS/DFS

mHCC - 1st line (L1) metastatic/advanced hepatocellular cancer (mHCC) mHCC - 1st line (L1)

versus sorafenib
atezolizumab plus bevacizumab vs. sorafenib 1 certainty unassessablestatistically conclusive-39% certainty unassessablestatistically conclusive-38%-